Duodenal Perforation Secondary to Erlotinib Therapy in a Patient With Non-Small Cell Lung Cancer

Rafiullah, MD; Wardah Sayed Shah, MBBS; Navid Abdul Majid, MD; Rezwan Islam, MD

ABSTRACT
Lung cancer is a lethal disease with high mortality, and treatment modality varies with type of tumor and stage of the disease. Targeted molecular therapies have been developed for patients with advanced non-small cell lung cancer. The presence of epidermal growth factor receptor (EGFR) mutation qualifies the patient for EGFR-TKI (tyrosine kinase inhibitor) therapy such as erlotinib, which is not without risk. We report an interesting case of duodenal perforation secondary to erlotinib therapy. This is the second reported case of bowel perforation after erlotinib therapy in a patient with advanced non-small cell lung cancer.

INTRODUCTION
According to most recent statistics, there are 526,510 individuals in the United States living with a history of lung cancer. It is estimated that an additional 224,390 cases will be diagnosed in 2016, with the median age at diagnosis of 70 years, although it has been reported that the number of lung cancer deaths has declined due to a decrease in smoking frequency. The choice of chemotherapy, surgery, radiotherapy, or a combination of therapies depends on the type of lung cancer, staging, and performance status of the patient, as well as patient choices. These therapies all can have substantial side effects and complications.

Research in the field of non-small cell lung cancer (NSCLC) has revealed that it is a combination of a heterogenous group of pathologies. Adjuvant chemotherapy is one of the most important treatment strategies for NSCLC. Research has shown cisplatin-based regimens have demonstrated survival benefits for stage II and stage IIIA disease. Targeted molecular therapies have been developed for patients with advanced NSCLC. The presence of epidermal growth factor receptor (EGFR) mutation qualifies the patient for EGFR-TKI (tyrosine kinase inhibitor) therapy such as erlotinib, gefitinib, and afatinib. Testing for EGFR mutation typically occurs only in patients with adenocarcinoma; however, EGFR-TKI therapy is appropriate for later line treatment of progressive metastatic disease in any histology type. Erlotinib is associated with some serious complications including fatal pulmonary toxicities, liver failure, and hepatorenal syndrome. One rare complication is gastrointestinal perforation. We report a case of duodenal perforation, which is the second reported case of bowel perforation after erlotinib therapy in a patient with advanced NSCLC.

CASE REPORT
A 53-year-old woman with a primary medical history of metastatic squamous cell lung cancer with an anaplastic component of undifferentiated carcinoma with mediastinal lymphadenopathy, who was receiving erlotinib, presented to the oncology clinic with abdominal pain. She had been seen in the oncology clinic 1 day before admission for shortness of breath. She did not have any chest pain and was saturating well on room air. Computed tomography (CT) of the chest showed no evidence of pulmonary embolism. When she presented again to the oncology clinic, she complained of abdominal pain that had started the night before, 8/10 in severity, was right-sided and radiating to the back. She reported nausea but no vomiting, and absolute constipation since morning. She has been compliant with erlotinib therapy for her lung cancer and denied any hematemesis or melena. She was admitted to the
erlotinib was stopped. She was followed by her oncologist and primary care physician with no further complications.

DISCUSSION

Carcinoma of the lung is the 7th leading cancer in women and the 8th leading cancer in men in the United States. Erlotinib is the second-line therapy for refractory and advanced NSCLC. The favorable response factors for erlotinib therapy are female gender, nonsmoker, Asian race, and adenocarcinoma. The most frequently reported side effect of erlotinib is skin rash (49%-85%). Other reported complications of erlotinib include diarrhea, anemia, muscle weakness, and, rarely, gastrointestinal perforation. The exact mechanism of erlotinib causing bowel perforation is not clear. Our patient had a history of steroid use (though the duration is not clear) and a vascular endothelial growth factor receptor (VEGFR) inhibitor (bevacizumab), which can potentially cause bowel ischemia leading to peptic ulcer disease. She did not have any record of endoscopy-proven peptic ulcer disease, but she was using proton pump inhibitors for gastrointestinal prophylaxis. There was no documented history of colonoscopy, bowel perforation, bowel surgery, diverticulosis, or any evidence of alternative etiology that may have led to the bowel perforation. Our patient had poor re-epithelization in the presence of erlotinib.

Cheon et al reported the case of a 66-year-old woman who developed an enterocutanoeus fistula secondary to erlotinib therapy for metastatic NSCLC. Theirs was the first reported case of...
bowel perforation secondary to erlotinib therapy in a patient with NSCLC. Their patient did not have bowel wall metastasis and had received erlotinib for 9 months before the bowel perforation.12 We are reporting a case of a 53-year-old woman who developed duodenal perforation after erlotinib therapy for advanced metastatic NSCLC. Our case is the 2nd reported case of bowel perforation secondary to erlotinib, similar in many respects to Cheon et al’s case: female, similar age group, and NSCLC. Our patient developed duodenal perforation after 47 days of erlotinib, while Cheon et al12 reported bowel perforation after 9 months of therapy. Our patient also did not have bowel metastasis at time of duodenal perforation.

In June 2012, a CT of the abdomen in our patient did not show any bowel wall metastasis, and the operative specimen of the bowel also did not show any bowel wall metastasis or evidence of cancer. The prescribing information for erlotinib states that patients at a high risk for gastrointestinal perforation and complications are those who have concomitant use of angiogenic therapy (VEGFR inhibitor, eg, bevacizumab), nonsteroidal anti-inflammatory medications, steroids, and taxane-based chemotherapy. Our patient was receiving only erlotinib as subsequent (not concomitant) monotherapy for 47 days before the duodenal perforation. Patients with a history of diverticular disease or peptic ulcer disease are also at increased risk of gastrointestinal complications secondary to erlotinib.13,14 Our patient had some of these risk factors, such as previous taxane-based chemotherapy, steroid use, and therapy with bevacizumab. Cheon et al’s patient also had some of these risk factors.12

CONCLUSION
Gastrointestinal perforation is a rare but potentially lethal complication of erlotinib therapy, especially in patients with risk factors like taxane-based therapy, steroid use, concomitant or previous therapy with bevacizumab, or other gastrointestinal comorbidities such as diverticular disease and peptic ulcer disease. This rare complication of erlotinib should be considered in patients who present with abdominal pain to prevent mortality.

Acknowledgements: The authors thank Marie Fleisner of the Marshfield Clinic Research Foundation’s Office of Scientific Writing and Publication for editorial assistance in the preparation of this report.

Funding/Support: None declared.

Financial Disclosures: None declared.

REFERENCES
The mission of WMJ is to provide a vehicle for professional communication and continuing education for Midwest physicians and other health professionals.

WMJ (ISSN 1098-1861) is published by the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in the Midwest. The managing editor is responsible for overseeing the production, business operation and contents of the WMJ. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socioeconomic, or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither WMJ nor the Wisconsin Medical Society take responsibility. WMJ is indexed in Index Medicus, Hospital Literature Index, and Cambridge Scientific Abstracts.

For reprints of this article, contact the WMJ at 866.442.3800 or e-mail wmj@wismed.org.

© 2017 Wisconsin Medical Society